When the Office of Inspector General issued its pharma marketing guidance in 2003, some experts predicted that drug companies would initially curtail their excesses, and after a while the feds would ease up and the pendulum would swing back to the middle, as had happened after other government crackdowns. But that was before the advent of Medicare Part D.
Register to view the full article
Register for MeetingsNet.com and gain access to premium content including the CMI 25 Listing, our monthly digital edition, the MeetingsNet app, live and on-demand webinars, and much more.
0 comments
Hide comments